Key result
Statin use linked to ~51% lower 1-month mortality in critically ill NSAH patients.
Why the study?
The impact of statin use on prognosis in critically ill patients with nontraumatic subarachnoid hemorrhage remains unclear.
Does statin use reduce all-cause mortality in critically ill patients with non-traumatic subarachnoid hemorrhage?
Cohort (n=750)
Does statin use reduce all-cause mortality in critically ill patients with non-traumatic subarachnoid hemorrhage?
Hazard Ratio: 0.49
p-value: p=<0.001
In a retrospective cohort of critically ill patients with non-traumatic subarachnoid hemorrhage, statin use was associated with a significant reduction in both short-term and 1-year all-cause mortality.
May support statin use in critically ill NSAH; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Nontraumatic subarachnoid hemorrhage (NSAH) is a type of hemorrhagic stroke with high mortality and low recovery rates. Although statins are commonly used in cardiovascular diseases, their impact on subarachnoid hemorrhage prognosis remains unclear. This study aimed to explore the relationship between statin use and short-term and long-term all-cause mortality in critically ill patients with NSAH. METHODS: Data from the Medical Information Mart for Intensive Care IV database were used to categorize critically ill patients with NSAH into statin and nonstatin groups. A Cox proportional hazards model assessed the association between statin use and all-cause mortality. Subgroup analyses were conducted to examine the consistency of statin effects on mortality. RESULTS: The study included 750 patients, with 43% male. One-month mortality was 21%, and intensive care unit mortality was 17%. Cox regression analysis showed that statin use was independently associated with reduced intensive care unit mortality (hazard ratio [HR = 0.52; P = 0.010), 1-month mortality (HR = 0.49; P < 0.001), 3-month mortality (HR = 0.62; P = 0.012), and 1-year mortality (HR = 0.70; P = 0.040). Subgroup analyses showed no significant interactions. Simvastatin and atorvastatin both significantly reduced 1-month mortality. CONCLUSIONS: Statin use may improve mortality outcomes in critically ill patients with NSAH, suggesting their potential benefit in this population.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in Non-traumatic subarachnoid hemorrhage (NSAH) (n=750). Statin use vs. Nonstatin use was evaluated on 1-month mortality (HR 0.49, p=<0.001). Statin use was independently associated with reduced 1-month mortality (HR 0.49; P<0.001) and intensive care unit mortality (HR 0.52; P=0.010) in critically ill patients with NSAH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: